TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
January 04, 2024 07:00 ET
|
TScan Therapeutics, Inc.
Reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting Clearance of INDs for four TCR-Ts, including a TCR-T for PRAME, in support...
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
December 09, 2023 12:00 ET
|
TScan Therapeutics, Inc.
No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical...
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
December 07, 2023 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
December 04, 2023 16:05 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
December 04, 2023 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
November 30, 2023 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 07:00 ET
|
TScan Therapeutics, Inc.
Company to present poster on initial data from heme malignancies Phase 1 trial at the 65th ASH Annual Meeting and Exposition; Company to host virtual KOL event on Monday, December 11, 2023, at 8:00...
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
November 06, 2023 07:00 ET
|
TScan Therapeutics, Inc.
Solid tumor program uses separate screening protocol designed to identify patients in advance of treatment protocol; on track to enroll first patient in study this year Company adds TSC-201-B0702 to...
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
November 02, 2023 09:05 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
September 27, 2023 09:06 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...